Study of a new drug for advanced solid tumors with a specific genetic feature
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older (19 in South Korea).
- Your cancer is advanced (locally advanced or spread to other parts of the body) and standard treatments have not worked, or you can't tolerate them.
- Your tumor has a specific genetic change called MTAP deficiency, which your doctor can test for.
- You are in good general health, able to care for yourself and do light activities (ECOG score 0-1).
- You have adequate organ function and are willing to provide a tumor tissue sample before treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
This study tests a new drug called GS-2426 for people with advanced solid tumors that have a specific genetic change called MTAP deficiency. It may be an option if other treatments have stopped working or are not available.
This study tests a new drug, BMS-986504, to see how it is processed and removed from the body in people with certain advanced solid tumors. It is for patients whose cancer has a specific genetic change (MTAP deletion) and who have no other good treatment options.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This trial tests a new combination of two study drugs (GH55 and GH21) for people with advanced solid tumors that have certain genetic changes. The goal is to see if the combo is safe and can help shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.